Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones.

[1]  Gang Bao,et al.  Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. , 2014, Cell reports.

[2]  W. Ge,et al.  TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. , 2014, Cell stem cell.

[3]  J. Keith Joung,et al.  Broad Specificity Profiling of TALENs Results in Engineered Nucleases With Improved DNA Cleavage Specificity , 2014, Nature Methods.

[4]  B. Conklin,et al.  Isolation of single-base genome-edited human iPS cells without antibiotic selection , 2014, Nature Methods.

[5]  David E. Paschon,et al.  LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction , 2014, Neurobiology of Disease.

[6]  Y. Hoki,et al.  Induced Pluripotent Stem Cell Generation-Associated Point Mutations Arise during the Initial Stages of the Conversion of These Cells , 2014, Stem cell reports.

[7]  J. I. Izpisúa Belmonte,et al.  A Cut above the Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem Cells* , 2013, The Journal of Biological Chemistry.

[8]  W. Seeley,et al.  Genetic Correction of Tauopathy Phenotypes in Neurons Derived from Human Induced Pluripotent Stem Cells , 2013, Stem cell reports.

[9]  Nicholas E. Propson,et al.  Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis , 2013, Proceedings of the National Academy of Sciences.

[10]  D. Goldstein,et al.  Sequencing studies in human genetics: design and interpretation , 2013, Nature Reviews Genetics.

[11]  Chad A. Cowan,et al.  Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. , 2013, Cell stem cell.

[12]  Torsten Kluba,et al.  Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. , 2013, Cell stem cell.

[13]  Kevin Kim,et al.  A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.

[14]  S. Salani,et al.  Genetic Correction of Human Induced Pluripotent Stem Cells from Patients with Spinal Muscular Atrophy , 2012, Science Translational Medicine.

[15]  J. Yates,et al.  Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 , 2012, Nature.

[16]  A. Bashashati,et al.  Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer , 2012, Genome research.

[17]  Christopher A. Miller,et al.  Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. , 2012, Cell stem cell.

[18]  Yutao Du,et al.  Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. , 2012, Cell stem cell.

[19]  George M. Church,et al.  Elevated Coding Mutation Rate During the Reprogramming of Human Somatic Cells into Induced Pluripotent Stem Cells , 2012, Stem cells.

[20]  F. Yi,et al.  Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs , 2011, Cell Research.

[21]  Jeffrey C. Miller,et al.  An unbiased genome-wide analysis of zinc-finger nuclease specificity , 2011, Nature Biotechnology.

[22]  A. Bradley,et al.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells , 2011, Nature.

[23]  Michael C. Rusch,et al.  CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.

[24]  C. L. Ramirez,et al.  Revealing Off-Target Cleavage Specificities of Zinc Finger Nucleases by In Vitro Selection , 2011, Nature Methods.

[25]  Susan Lindquist,et al.  Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.

[26]  J. I. Izpisúa Belmonte,et al.  Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. , 2011, Cell stem cell.

[27]  J. Yates,et al.  Recapitulation of premature aging with iPSCs from Hutchinson-Gilford progeria syndrome , 2011, Nature.

[28]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[29]  R. Jaenisch,et al.  Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases , 2009, Nature Biotechnology.

[30]  Prashant Mali,et al.  Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. , 2009, Cell stem cell.

[31]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[32]  Luigi Naldini,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[33]  B. Shafer,et al.  The roles of REV3 and RAD57 in double-strand-break-repair-induced mutagenesis of Saccharomyces cerevisiae. , 2002, Genetics.

[34]  J. Strathern,et al.  A role for REV3 in mutagenesis during double-strand break repair in Saccharomyces cerevisiae. , 1997, Genetics.

[35]  B. Shafer,et al.  DNA synthesis errors associated with double-strand-break repair. , 1995, Genetics.